Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC
Status:
Completed
Trial end date:
2019-04-02
Target enrollment:
Participant gender:
Summary
This research is being done because further research on selumetinib in combination with
standard chemotherapy treatment is needed. Although the number of treatment options for
patients with advanced non-small cell lung cancer has increased over the past decade,
prognosis remains poor, and there is a need for additional therapeutic options.